Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | GRM5 | P41594 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3435028 | 0.95 | CYP1A2 (0.63) | CYP1A2CYP2C9CYP2C19GRM5LMNA | |
| SCHEMBL3434300 | 0.82 | P2RX7 (0.50) | CYP1A2CYP2C9CYP2C19ALDH1A1HSD11B1 | |
| SCHEMBL3435664 | 0.81 | MAPT (0.50) | GRM5LMNAALDH1A1MAPTL3MBTL1 | |
| SCHEMBL3436525 | 0.81 | P2RX7 (0.49) | POLBHSD11B1P2RX7 | |
| SCHEMBL5795083 | 0.80 | CYP1A2 (1.00) | CYP1A2CYP2C9CYP2C19GRM5LMNA | |
| SCHEMBL29577310 | 0.80 | CYP1A2 (1.00) | CYP1A2CYP2C9CYP2C19GRM5LMNA | |
| SCHEMBL6708175 | 0.80 | CYP1A2 (1.00) | CYP1A2CYP2C9CYP2C19GRM5LMNA | |
| SCHEMBL781659 | 0.80 | CYP1A2 (0.87) | CYP1A2CYP2C9CYP2C19GRM5LMNA | |
| Hydrochloric Acid SCHEMBL27538332 | 0.79 | CYP1A2 (0.97) | CYP1A2CYP2C9CYP2C19GRM5LMNA | |
| SCHEMBL3434236 | 0.77 | MAPK1 (0.43) | CYP1A2CYP2C9CYP2C19LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | CYP1A2 1955/4885CYP2C9 2215/4885CYP2C19 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.